Boston Scientific
- Left Atrial Appendage Closure (LAAC)
- Mapping and Ablation
- Venous Therapies
- Cardiac Rhythm Management
- Structural Heart
- Interventional Oncology
- Drug-Eluting Technologies
- Coronary
Playback speed
10 seconds
LEGACY: A Multicenter Study Confirming TheraSphere™ as a Neoadjuvant or Standalone Therapy in Treating HCC
By
Boston Scientific
FEATURING
Vivian Bishay
By
Boston Scientific
FEATURING
Vivian Bishay
768 views
October 19, 2020
The LEGACY study is a multicenter, retrospective study demonstrating reproducible treatment outcomes across multiple centers and confirms published outcomes previously published in single center studies. This presentation provides background on the use of Y-90 glass microsphere to treat HCC, discusses results of the LEGACY study and recently published studies using Y-90 glass microspheres.
Login to view comments.
Click here to Login
Interventional Oncology
Wed, Nov 3, 2021
Faculty: Boston Scientific , Riad Salem , Juan Gimenez , Robert Lewandowski , Shamar Young
Faculty: Boston Scientific , Riad Salem , Juan Gimenez , Robert Lewandowski , Shamar Young